These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 26210287)

  • 1. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
    Wang L; Wang H; Wang JH; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Zhang YJ
    Oncotarget; 2015 Oct; 6(30):30317-26. PubMed ID: 26210287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.
    Ito Y; Kimura H; Maeda Y; Hashimoto C; Ishida F; Izutsu K; Fukushima N; Isobe Y; Takizawa J; Hasegawa Y; Kobayashi H; Okamura S; Kobayashi H; Yamaguchi M; Suzumiya J; Hyo R; Nakamura S; Kawa K; Oshimi K; Suzuki R
    Clin Cancer Res; 2012 Aug; 18(15):4183-90. PubMed ID: 22675173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein-Barr virus DNA load in NK/T-cell lymphoma treated with P-GEMOX protocol.
    Wang XX; Li PF; Bai B; Gao Y; Rong QX; Cai QQ; Lin SX; Zhang YJ; Li ZM; Jiang WQ; Huang HQ
    Leuk Lymphoma; 2019 Aug; 60(8):1917-1925. PubMed ID: 30646796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution.
    Huang Y; Rao H; Yan S; Wang F; Wu Q; Feng Y; Zhang Y
    Ann Hematol; 2017 Aug; 96(8):1331-1342. PubMed ID: 28550598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma.
    Cho J; Kim SJ; Park S; Yoo KH; Ki CS; Ko Y; Kim WS
    Ann Hematol; 2018 Aug; 97(8):1427-1436. PubMed ID: 29627879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy.
    Wang ZY; Liu QF; Wang H; Jin J; Wang WH; Wang SL; Song YW; Liu YP; Fang H; Ren H; Wu RY; Chen B; Zhang XM; Lu NN; Zhou LQ; Li YX
    Blood; 2012 Sep; 120(10):2003-10. PubMed ID: 22826562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T/NK cell type chronic active Epstein-Barr virus disease in adults: an underlying condition for Epstein-Barr virus-associated T/NK-cell lymphoma.
    Isobe Y; Aritaka N; Setoguchi Y; Ito Y; Kimura H; Hamano Y; Sugimoto K; Komatsu N
    J Clin Pathol; 2012 Mar; 65(3):278-82. PubMed ID: 22247563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].
    Hou X; Zhang L; Zhao C; Li S; Lu LX; Han F; Shao JY; Huang PY
    Ai Zheng; 2006 Jul; 25(7):785-92. PubMed ID: 16831265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiotherapy improves survival in early stage extranodal natural killer/T cell lymphoma patients receiving asparaginase-based chemotherapy.
    Li YY; Feng LL; Niu SQ; Wang HY; Zhang LL; Wang L; Xia ZJ; Huang HQ; Xia YF; Zhang YJ; Wang XC
    Oncotarget; 2017 Feb; 8(7):11480-11488. PubMed ID: 28002792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus-positive nodal T/NK-cell lymphoma: an analysis of 15 cases with distinct clinicopathological features.
    Jeon YK; Kim JH; Sung JY; Han JH; Ko YH;
    Hum Pathol; 2015 Jul; 46(7):981-90. PubMed ID: 25907865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcome of patients with advanced stage natural killer/T-cell lymphoma: elucidating the effects of asparaginase and postchemotherapeutic radiotherapy.
    Bi XW; Jiang WQ; Zhang WW; Huang JJ; Xia Y; Wang Y; Sun P; Li ZM
    Ann Hematol; 2015 Jul; 94(7):1175-84. PubMed ID: 25687842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis.
    Kim SJ; Choi JY; Hyun SH; Ki CS; Oh D; Ahn YC; Ko YH; Choi S; Jung SH; Khong PL; Tang T; Yan X; Lim ST; Kwong YL; Kim WS;
    Lancet Haematol; 2015 Feb; 2(2):e66-74. PubMed ID: 26687611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.
    Wang H; Wang L; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Li ZM; Lu Y
    Oncotarget; 2016 May; 7(22):33035-45. PubMed ID: 27105512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area.
    Alfieri S; Iacovelli NA; Marceglia S; Lasorsa I; Resteghini C; Taverna F; Mazzocchi A; Orlandi E; Guzzo M; Bianchi R; Fanti D; Pala L; Racca S; Dvir R; Quattrone P; Gloghini A; Volpi CC; Granata R; Bergamini C; Locati L; Licitra L; Bossi P
    Oncotarget; 2017 Jul; 8(29):47780-47789. PubMed ID: 28562354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. L-Asparaginase monotherapy for EBV-positive T/NK lymphoproliferative diseases: A pilot Study.
    Jinta M; Imadome K; Komatsu H; Yoshimori M; Kurata M; Fujiwara S; Miura O; Arai A
    J Med Dent Sci; 2015 Mar; 62(1):1-9. PubMed ID: 26111530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
    Yoon DH; Kim SJ; Jeong SH; Shin DY; Bae SH; Hong J; Park SK; Yhim HY; Yang DH; Lee H; Kang HJ; Lee MH; Eom HS; Kwak JY; Lee JH; Suh C; Kim WS
    Oncotarget; 2016 Dec; 7(51):85584-85591. PubMed ID: 27542213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type.
    Suzuki R; Yamaguchi M; Izutsu K; Yamamoto G; Takada K; Harabuchi Y; Isobe Y; Gomyo H; Koike T; Okamoto M; Hyo R; Suzumiya J; Nakamura S; Kawa K; Oshimi K;
    Blood; 2011 Dec; 118(23):6018-22. PubMed ID: 21984805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epstein-Barr virus-associated natural killer/T-cell lymphomas.
    Asano N; Kato S; Nakamura S
    Best Pract Res Clin Haematol; 2013 Mar; 26(1):15-21. PubMed ID: 23768637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and management of extranodal NK/T cell lymphoma nasal type.
    Tse E; Kwong YL
    Expert Rev Hematol; 2016 Sep; 9(9):861-71. PubMed ID: 27347812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma.
    Okamoto A; Yanada M; Miura H; Inaguma Y; Tokuda M; Morishima S; Kanie T; Yamamoto Y; Mizuta S; Akatsuka Y; Yoshikawa T; Mizoguchi Y; Nakamura S; Okamoto M; Emi N
    Cancer Sci; 2015 Nov; 106(11):1576-81. PubMed ID: 26353084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.